Nerviano Medical Sciences’ presentation from the 8th Annual DDR Inhibitors Summit is now available
We’re thrilled to share the presentation delivered by Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, Guest Speaker at the recent 8th Annual DDR Inhibitors Summit. Lisa’s presentation “Exploring Next-Gen PARP Inhibitors without PARP Trapping” focused on preclinical features and preliminary clinical data of the highly unique non-trapping, PARP1 […]
Nerviano Medical Sciences is presenting at the 8th Annual DDR Inhibitors Summit
We are excited to announce that Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, will participate as a Guest Speaker at the 8th Annual DDR Inhibitors Summit taking place in Boston from January 28-30. Lisa’s presentation Exploring Next-Gen PARP Inhibitors without PARP Trapping, scheduled for January 30th at 3:45 […]
Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma
Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma NERVIANO, Italy and BOSTON, Mass.,13 January 2025 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., […]
Nerviano Medical Sciences S.r.l. Announces the Launch of a New Clinical Trial to Evaluate NMS-153 in Combination with Atezolizumab and Clinical Trial Supply Agreement with Roche
Nerviano Medical Sciences S.r.l. Announces the Launch of a New Clinical Trial to Evaluate NMS-153 in Combination with Atezolizumab and Clinical Trial Supply Agreement with Roche NMS-153: A clinical-stage, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 (MPS1), and cGAS/STING pathway activator, with differentiated mechanism of action and potential for First-in-Class/Best-in-Class The […]
Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results
Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results Agreement reached with Merck KGaA to gain back the full rights of NMS-293 Available clinical data support NMS-293 as an ideal partner for combination with DNA-damaging agents like chemotherapies or ADC payloads: NMS […]
Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts
Perron U, Grassi E, Chatzipli A, Viviani M, Karakoc E, Trastulla L, Brochier LM, Isella C, Zanella ER, Klett H, Molineris I, Schueler J, Esteller M, Medico E, Conte N, McDermott U, Trusolino L, Bertotti A, Iorio F Nat Commun (2024), 15(1), 9139
New LsrK Ligands as AI-2 Quorum Sensing Interfering Compounds against Biofilm Formation
Milli G, Pellegrini A, Listro R, Fasolini M, Pagano K, Ragona L, Pietrocola G, Linciano P, Collina S Med Chem (2024), 67(20), 18139-18156
Nerviano Medical Sciences Announces Strategic acquisition of atamparib, a Phase II-ready PARP7 Inhibitor, from Ribon Therapeutics
NERVIANO, Italy and BOSTON, Mass., November 14, 2024 – Nerviano Medical Sciences S.r.l. (NMS) – a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Srl – a global leader in oncological innovation with a leading position in PARP1 inhibitor clinical development in brain cancer, is […]
Nerviano Medical Sciences at BIO-Europe 2024
Nerviano Medical Sciences is excited to announce the participation in BIO-Europe 2024, Europe’s premier life sciences partnering event. – In-Person Event: November 4–6, 2024, Stockholm, Sweden – Digital Partnering: November 12–13, 2024 We look forward to meeting you at the event and discussing potential collaborations. Please click here for more details and to connect with […]
Nerviano Medical Sciences announces publication of the paper “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents”
We are pleased to announce the publication of our review article titled “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents” in Pharmaceuticals, as part of the Special Issue “Evaluation of the Antitumor Mechanism of Armed Antibodies: 2nd Edition“. This paper explores the latest advances in the use of DNA-interacting agents […]
